We are leveraging our deep understanding of recent biological discoveries to build our clinical pipeline. Our focus is on advancing the development of novel, potentially first-in-class treatments for diseases with significant unmet need.
(AZP-531) is an unacylated ghrelin analogue with a novel mechanism of action, for the treatment of Prader-Willi syndrome (PWS)
(ATR-101) is an ACAT1 inhibitor being investigated in classic congenital adrenal hyperplasia (CAH)
is a reversible antagonist of the human neurokinin 3 recepter (NK3R) in development for the treatment of vasomotor symptoms
associated with menopause.